GlobeNewswire: Capricor Therapeutics, Inc. Contains the last 10 of 97 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:39:36ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/12/19/1963048/0/en/Capricor-Therapeutics-Announces-Closing-of-5-1-Million-Offering-Priced-At-the-Market.html?f=22&fvtc=4&fvtv=20730Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market2019-12-19T18:14:21Z<![CDATA[LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced the closing of the previously announced offering priced at-the-market of 4,139,477 shares of the Company’s common stock (or common stock equivalents), at a purchase price of $1.226 per share and associated warrant. In addition, select members of the Company's Board of Directors participated in the offering. Each share of common stock (or common stock equivalent) offered was sold with a warrant to purchase one share of common stock at an exercise price of $1.10 per share and a five-year term.]]>https://www.globenewswire.com/news-release/2019/12/17/1961826/0/en/Capricor-Therapeutics-Announces-Pricing-of-5-1-Million-Offering-Priced-At-the-Market.html?f=22&fvtc=4&fvtv=20730Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market2019-12-17T18:52:03Z<![CDATA[LOS ANGELES, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced that it has entered into a definitive securities purchase agreement with a single, healthcare-dedicated institutional investor for the purchase in an offering priced at-the-market of 4,078,304 shares of the Company’s common stock (or common stock equivalents), at a purchase price of $1.226 per share and associated warrant. In addition, select members of the Company's Board of Directors are participating in the offering. Each share of common stock (or common stock equivalent) offered was sold with a warrant to purchase one share of common stock at an exercise price of $1.10 per share and a five-year term.]]>https://www.globenewswire.com/news-release/2019/11/07/1943481/0/en/Capricor-Therapeutics-Reports-Third-Quarter-2019-Financial-Results-and-Provides-Recent-Corporate-Update.html?f=22&fvtc=4&fvtv=20730Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update2019-11-07T21:00:00Z<![CDATA[Provides Update on End of Phase Type-B Meeting with FDA]]>https://www.globenewswire.com/news-release/2019/11/01/1939509/0/en/Capricor-Therapeutics-to-Present-Third-Quarter-2019-Financial-Results-and-Recent-Corporate-Update-on-November-7.html?f=22&fvtc=4&fvtv=20730Capricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 72019-11-01T13:00:00Z<![CDATA[LOS ANGELES, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its third quarter of 2019 financial results and corporate update shortly after the NASDAQ market close on Thursday, November 7. Management will then host a webcast and conference call at 4:30 p.m. ET on November 7.]]>https://www.globenewswire.com/news-release/2019/10/21/1932635/0/en/Capricor-Therapeutics-to-Host-Key-Opinion-Leader-Call-on-the-Role-of-CAP-1002-for-the-Treatment-of-Duchenne-Muscular-Dystrophy-DMD.html?f=22&fvtc=4&fvtv=20730Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)2019-10-21T13:25:00Z<![CDATA[Call Scheduled for Thursday, October 24th at 10:30am Eastern Time]]>https://www.globenewswire.com/news-release/2019/10/07/1925690/0/en/Capricor-Presents-Additional-Positive-Data-from-Ongoing-HOPE-2-Study-of-CAP-1002-in-Duchenne-Muscular-Dystrophy-at-World-Muscle-Society-Data-Demonstrates-Improved-PUL-2-0-Performan.html?f=22&fvtc=4&fvtv=20730Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months2019-10-07T10:30:00Z<![CDATA[--Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies----Company to Host Conference Call Today at 5:30 AM PT / 8:30 AM ET--]]>https://www.globenewswire.com/news-release/2019/10/02/1924150/0/en/Capricor-to-Present-Interim-Results-from-the-HOPE-2-Trial-in-a-Late-Breaking-Session-of-the-World-Muscle-Society-and-Company-to-Host-Conference-Call-Monday-October-7-at-5-30-AM-PT-.html?f=22&fvtc=4&fvtv=20730Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET2019-10-02T13:15:00Z<![CDATA[LOS ANGELES, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announced that it will present interim results from the randomized, double-blind, Phase II HOPE-2 clinical trial of CAP-1002 in boys and young men with Duchenne muscular dystrophy (DMD) at the 24th International Congress of the World Muscle Society. The International Congress of the World Muscle Society will be held October 1 – 5, 2019 at Tivoli Gardens in Copenhagen, Denmark.]]>https://www.globenewswire.com/news-release/2019/09/24/1919808/0/en/Capricor-Therapeutics-to-Meet-with-FDA-to-Discuss-CAP-1002-to-Treat-Duchenne-Muscular-Dystrophy.html?f=22&fvtc=4&fvtv=20730Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy2019-09-24T11:30:00Z<![CDATA[Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies]]>https://www.globenewswire.com/news-release/2019/09/17/1916542/0/en/Capricor-Therapeutics-to-Present-Results-from-the-HOPE-2-Trial-of-CAP-1002-in-Duchenne-Muscular-Dystrophy-in-a-Late-Breaking-Session-of-the-World-Muscle-Society.html?f=22&fvtc=4&fvtv=20730Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society2019-09-17T11:00:00Z<![CDATA[Dr. Craig McDonald to Provide Update in Late Breaking Oral Presentation Dr. Craig McDonald to Provide Update in Late Breaking Oral Presentation]]>https://www.globenewswire.com/news-release/2019/09/06/1912117/0/en/Capricor-Therapeutics-to-Present-at-Upcoming-Conferences.html?f=22&fvtc=4&fvtv=20730Capricor Therapeutics to Present at Upcoming Conferences2019-09-06T11:30:00Z<![CDATA[LOS ANGELES, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced that that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at two upcoming conferences:]]>